6:07 AM
 | 
Oct 24, 2018
 |  BC Extra  |  Clinical News

Oyster Point's OC-01 dry eye nasal spray meets in Phase IIb

Oyster Point Pharma Inc. (Princeton, N.J.) said all three doses of OC-01 met the primary endpoint of improving tear production in the Phase IIb ONSET trial to treat dry eye disease. The company also reported Wednesday that its other nicotinic acetylcholine receptor (nAchR) agonist nasal spray, OC-02, missed the same endpoint in the Phase IIb RAINIER trial in the indication.

OC-01 and OC-02 are both potential first-in-class, ocular-surface sparing treatments designed to stimulate...

Read the full 345 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >